A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).

Taichi TakashinaHajime AsahinaSatoshi OizumiNoriyuki YamadaMasao HaradaKei TakamuraHiroshi YokouchiToshiyuki HaradaOsamu HonjoTakahiro OgiNaoto MorikawaIchiro KinoshitaRyoichi HondaKosuke NakanoKenya KanazawaToraji AmanoHirotoshi Dosaka-AkitaHiroshi IsobeMasaharu Nishimuranull null

Published in: International journal of clinical oncology (2018)

UMIN000005872.

Keyphrases

phase ii study
wild type
small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
metastatic colorectal cancer
open label
locally advanced
high grade
tyrosine kinase
placebo controlled
low grade
rectal cancer
squamous cell carcinoma
randomized controlled trial
study protocol